Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Arranon cancer drug receives advisory committee support
October 23rd, 2005
Baylor College of Medicine oncology patients received a small dose of hope last week when Arranon (nelarabine) Injection, a cancer-fighting drug, was recommended for accelerated approval by the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA). Arranon is targeted towards adult and pediatric patients fighting T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), - blood cancers that affect how the body makes blood and provides immunity from other diseases. The new drug, developed by GlaxoSmithKline (GSK), would be an option for patients whose disease has not responded to or has relapsed following at...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
